Skip to main content

Table 1 Pretreatment pathoclinical characteristics of the 599 patients eligible for this study

From: Serum apolipoprotein B to apolipoprotein A-I ratio is an independent predictor of liver metastasis from locally advanced rectal cancer in patients receiving neoadjuvant chemoradiotherapy plus surgery

Characteristic Value
Age at diagnosis (years old) 56 (18–75)
No. of patients by gender  
Male 396 (66.1%)
Female 203 (33.9%)
No. of patients by tumor differentiation  
Low 63 (10.5%)
Moderate 458 (76.5%)
High 78 (13.0%)
Distance to anal verge (cm) 5.0 (1.0–15.0)
No. of patients by clinical T stage  
cT4b 26 (4.3%)
cT4a 249 (41.6%)
cT3 314 (52.4%)
cT2 10 (1.7%)
cT1 0 (0.0%)
No. of patients by clinical N stage  
cN2 213 (35.6%)
cN1 280 (46.7%)
cN0 106 (17.7%)
CEA (ng/ml) 4.2 (0.0-392.0)
CA19-9 (U/ml) 13.8 (0.0-985.6)
ApoAI (g/L) 1.19 (0.51–2.05)
ApoB (g/L) 0.90 (0.39–1.78)
ApoB-to-apoAI ratio 0.75 (0.23–1.92)
No. of patients by radiotherapy technique  
3DCRT 163 (27.2%)
IMRT 436 (72.8%)
No. of patients by TRG  
5 16 (2.7%)
4 107 (17.8%)
3 202 (33.7%)
2 137 (22.9%)
1 137 (22.9%)
No. of patients by pathological T stage  
pT4b 13 (2.2%)
pT4a 36 (6.0%)
pT3 240 (40.1%)
pT2 135 (22.5%)
pT1 24 (4.0%)
pT0 151 (25.2%)
No. of patients by pathologic N stage  
pN2 26 (4.3%)
pN1 103 (17.2%)
pN0 470 (78.5%)
Chemotherapy cycle 7 (4–10)
No. of patients by active viral hepatitis  
Yes 82 (13.7%)
No 517 (86.3%)
  1. Abbreviations: CEA carcinoembryonic antigen; CA19-9 carbohydrate antigen 19 − 9; apoAI apolipoprotein A-I; apoB apolipoprotein B; 3DCRT three-dimensional conformal radiation therapy; IMRT, intensified modulated radiation therapy; TRG, tumor regression grade